Combination of Carmustine and Selenite Inhibits EGFR Mediated Growth Signaling in Androgen‐Independent Prostate Cancer Cells
- 25 May 2017
- journal article
- research article
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 118 (12) , 4331-4340
Abstract
Although aberrant androgen receptor (AR) signaling is a central mechanism for castration resistant prostate cancer (CRPC) progression, AR‐independent growth signaling is also present in CRPC. The current therapeutic options for patients with CRPC are limited and new drugs are desperately needed to eliminate these crucial growth signaling pathways. We have previously shown that combination of carmustine and selenite effectively induces apoptosis and growth inhibition by targeting AR and AR‐variants in CRPC cells. High levels of EGFR expression present in the CRPC cells mediates the cell proliferation via AR‐independent growth signaling mechanisms. Therefore, in this study, we investigated whether the combination of carmustine and selenite could inhibit EGFR mediated growth signaling and induce apoptosis in androgen independent‐AR negative prostate cancer cells. EGF exposure dose and time dependently increased phospho‐EGFR (Tyr845, Tyr1068, and Tyr1045), pAkt (Ser473), and pERK1/2 (Thr204/Tyr202) protein expression levels in AIPC cells. Combination of carmustine and selenite treatment markedly suppressed EGF‐stimulated proliferation and survival of AIPC cells and effectively induced apoptosis. The ROS generated by the combination of carmustine and selenite exhibited a strong inhibition on EGF stimulated EGFR and its downstream signaling molecules such as Akt, NF‐kB, ERK1/2, and Cyclin D1. Individual agent treatment showed only partial effect. Overall, our findings demonstrated that the combination of carmustine and selenite treatment dramatically inhibits EGFR signaling, proliferation, and induces apoptosis in AIPC cells, suggesting a potential candidate for the treatment of CRPC. The results of the study further suggest that the combination of carmustine and selenite treatment can overcome EGFR mediated AR‐independent growth response in CRPC during anti‐androgen therapy. J. Cell. Biochem. 118: 4331–4340, 2017.Keywords
Funding Information
- Henry Ford Health System (H10062, A10265)
This publication has 36 references indexed in Scilit:
- Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted TherapiesEuropean Urology, 2015
- Targeting Nuclear Factor-Kappa B to Overcome Resistance to ChemotherapyFrontiers in Oncology, 2013
- Abiraterone and Increased Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2011
- Akt‐mediated regulation of NFκB and the essentialness of NFκB for the oncogenicity of PI3K and AktInternational Journal of Cancer, 2009
- Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletionNature Reviews Endocrinology, 2009
- MAP kinase signalling pathways in cancerOncogene, 2007
- Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell linesEndocrine-Related Cancer, 2005
- Reduction of PTEN and p27kip1 expression correlates with tumor grade in prostate cancer. Analysis in radical prostatectomy specimens and needle biopsiesVirchows Archiv, 2004
- MITOGENIC SIGNALING IN ANDROGEN SENSITIVE AND INSENSITIVE PROSTATE CANCER CELL LINESJournal of Urology, 2000
- IMMUNOHISTOCHEMICAL COMPARATIVE ANALYSIS OF TRANSFORMING GROWTH FACTOR α, EPIDERMAL GROWTH FACTOR, AND EPIDERMAL GROWTH FACTOR RECEPTOR IN NORMAL, HYPERPLASTIC AND NEOPLASTIC HUMAN PROSTATESCytokine, 1999